McElroy S L, Frye M, Denicoff K, Altshuler L, Nolen W, Kupka R, Suppes T, Keck P E, Leverich G S, Kmetz G F, Post R M
Stanley Foundation Bipolar Treatment Outcome Network, Department of Psychiatry, University of Cincinnati College of Medicine, OH 45267, USA.
J Affect Disord. 1998 May;49(2):119-22. doi: 10.1016/s0165-0327(98)00002-0.
We evaluated the response to olanzapine in 14 consecutive patients with bipolar I disorder who were inadequately responsive to standard psychotropic agents.
Fourteen patients with bipolar I disorder by DSM-IV criteria experiencing persistent affective symptoms inadequately responsive to at least one standard mood stabilizer were treated with open-label olanzapine by one of the authors. Response was assessed with the Clinical Global Impression Scale modified for use in bipolar disorder (CGI-BP).
The 14 patients received olanzapine at a mean (SD dosage of 14.1+/-7.2 (range 5-30) mg/day for a mean+/-SD of 101.4+/-56.3 (range 30-217) days of treatment. Of the 14 patients, 8 (57%) displayed much or very much overall improvement in their illness. In general, olanzapine was well tolerated. The most common side effects were sedation, tremor, dry mouth, and appetite stimulation with weight gain.
Data were obtained nonblindly and without a randomized control group, and olanzapine was added to ongoing psychotropic regimens.
Olanzapine may have antimanic and mood-stabilizing effects in some patients with bipolar disorder, and is generally well tolerated. Controlled studies of olanzapine in bipolar disorder appear warranted.
我们评估了14例连续的双相I型障碍患者对奥氮平的反应，这些患者对标准精神药物反应欠佳。
14例符合DSM-IV标准的双相I型障碍患者，存在持续性情感症状，对至少一种标准心境稳定剂反应欠佳，由其中一位作者采用开放标签的奥氮平进行治疗。使用为双相障碍修改的临床总体印象量表（CGI-BP）评估反应。
14例患者接受奥氮平治疗，平均（标准差）剂量为14.1±7.2（范围5 - 30）mg/天，平均（标准差）治疗101.4±56.3（范围30 - 217）天。14例患者中，8例（57%）病情总体有很大或非常大的改善。总体而言，奥氮平耐受性良好。最常见的副作用是镇静、震颤、口干以及食欲增加伴体重增加。
数据是在非盲法且无随机对照组的情况下获得的，并且奥氮平是添加到正在进行的精神药物治疗方案中的。
奥氮平可能对一些双相障碍患者有抗躁狂和心境稳定作用，且总体耐受性良好。对奥氮平治疗双相障碍进行对照研究似乎是必要的。
